A handbook for leaders and managers
The World Health Organization (WHO) Global Status Report on Noncommunicable Diseases 2010 projects that noncommunicable diseases (NCDs) will be responsible for over 44 million deaths during the next decade, representing an increase of about 15% since 2010. Most of these deaths will occur in the WHO ...regions of Africa, South-East Asia and the Eastern Mediterranean. In the African Region alone, NCDs will cause around 3.9 million deaths by 2020.
more
Methodological field approaches for scientists with a basic background in entomology to prepare and implement a yellow fever entomological assessment during outbreaks
The survey aimed at evaluating the quality of selected antimalarials in six countries of sub-Saharan Africa (Cameroon, Ethiopia, Ghana, Kenya, Nigeria and the United Republic of Tanzania). These countries have been supported by WHO to strengthen their regulatory controls o...ver antimalarial products. The survey was organized independently of manufacturers of antimalarial medicines.
more
It provides insight into WHO’s work that aims to improve the health of the people of the United Republic of Tanzania in collaboration with key stakeholders.
This study was carried out to better understand the local beliefs and practices likely to enhance or hinder efforts to respond to the Ebola Virus Disease outbreak in Liberia.
AstraZeneca-SKBio in South Korea and Serum Institute of India
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
During the Programme Managers’ Review Meeting of Central and East Africa and South-East Asia (online meeting, June 2022), experts proposed additional regional and national subtargets related to VL incidence, as defined below. These targets can be revisited as progress is reviewed and access to dia...gnosis and treatment and surveillance improves.
more